NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 22 04:00PM ET
2.00
Dollar change
+0.23
Percentage change
12.97
%
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand27.00M Perf Week-3.63%
Market Cap187.38M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-9.52%
Income- PEG- EPS next Q- Inst Own0.06% Short Float- Perf Quarter-0.52%
Sales- P/S- EPS this Y- Inst Trans-0.35% Short Ratio1.19 Perf Half Y2.54%
Book/sh- P/B- EPS next Y- ROA- Short Interest0.01M Perf Year-81.90%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.69 - 15.55 Perf YTD-25.53%
Dividend Est.- P/FCF- EPS past 5Y-90.92% ROI- 52W High-87.14% Beta-0.60
Dividend TTM- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low18.32% ATR (14)0.19
Dividend Ex-DateAug 13, 2008 Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)48.98 Volatility9.35% 7.72%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q- Payout- Rel Volume74.23 Prev Close1.77
Sales Surprise- EPS Surprise66.98% Sales Q/Q- Earnings- Avg Volume5.37K Price2.00
SMA200.10% SMA50-6.65% SMA200-17.06% Trades Volume398,677 Change12.97%
Date Action Analyst Rating Change Price Target Change
Sep-04-24Initiated H.C. Wainwright Buy $9
Oct-24-23Initiated Cantor Fitzgerald Overweight $30
Apr-10-25 08:00AM
Aug-08-24 08:30AM
08:00AM
Jun-04-24 07:28AM
May-23-24 09:03PM
08:00AM Loading…
May-22-24 08:00AM
May-15-24 09:40AM
Apr-25-24 09:40AM
Mar-29-24 06:00AM
Nov-17-23 07:30AM
Oct-23-23 08:12AM
Oct-03-23 12:05PM
Sep-29-23 02:46AM
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.